What are the side effects of retatrutide?

Reported events are dominated by gastrointestinal effects — nausea, vomiting, diarrhoea and constipation — rising with dose. TRIUMPH-1 reported 11.3% discontinuation for adverse events on the 12 mg arm against 4.9% on placebo.

Does retatrutide cause burping?

Eructation is a recognised effect across incretin agonists, attributed to delayed gastric emptying rather than anything specific to retatrutide.

Does retatrutide affect sleep?

Sleep disturbance is discussed informally but does not appear as a notable finding in the published trials. It should not be presented as a documented effect.

Retatrutide Research

Retatrutide Side Effects Reported So Far

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-312 cited sources

Gastrointestinal effects dominate the reported profile — nausea, vomiting, diarrhoea and constipation — and they scale with dose. TRIUMPH-1 reported 11.3% discontinuation for adverse events on the 12 mg arm against 4.9% on placebo. Several effects discussed informally, including sleep disturbance, have no trial support.

Key facts

Dominant category: Gastrointestinal
Discontinuation, 12 mg arm: 11.3%
Discontinuation, placebo: 4.9%
Dose relationship: Events rise with dose
Long-term safety: Not established

What the trials actually reported

Nausea, vomiting, diarrhoea and constipation are the events reported most often, which is consistent across this whole drug class rather than specific to retatrutide. They were dose-dependent: higher arms reported more. The headline tolerability figure is discontinuation for adverse events, 11.3% on the 12 mg arm against 4.9% on placebo, which is a meaningful difference and the number worth carrying away.

Burping, and why it comes up

Eructation is a recognised effect across incretin agonists and is thought to follow from delayed gastric emptying rather than anything specific to a triple agonist. It appears in the adverse event tables for this class generally. It is a real, commonly discussed effect and it is also a minor one relative to the discontinuation figures above.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Effects that are discussed but not evidenced

Sleep disturbance is raised frequently in informal discussion and does not appear as a notable finding in the published retatrutide trials. That is not the same as it not happening — trials measure what they set out to measure — but nobody should present it as a documented effect, and several sites do.

What more receptors seems to cost

Across this class, adding receptor coverage has generally meant more gastrointestinal burden. Retatrutide engages three receptors and its reported discontinuation rate is higher than figures reported for dual and single agonists — though those come from different trials, so the comparison is indirect rather than measured.

And none of it describes research material

These figures come from participants in registered clinical trials receiving a manufactured investigational product under supervision. Material supplied for laboratory research is not that product and is not supplied for use in people.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance — the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator — FDA, EMA, or MHRA — has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press — but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA — HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals — research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water — never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

What are the side effects of retatrutide?: Reported events are dominated by gastrointestinal effects — nausea, vomiting, diarrhoea and constipation — rising with dose. TRIUMPH-1 reported 11.3% discontinuation for adverse events on the 12 mg arm against 4.9% on placebo.
Does retatrutide cause burping?: Eructation is a recognised effect across incretin agonists, attributed to delayed gastric emptying rather than anything specific to retatrutide.
Does retatrutide affect sleep?: Sleep disturbance is discussed informally but does not appear as a notable finding in the published trials. It should not be presented as a documented effect.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum